Acrivon Therapeutics (ACRV) Research & Development (2022 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Research & Development of $15.2 million for Q1 2026, down 1.61% year-over-year from $15.4 million in Q1 2025, and up 2.85% quarter-over-quarter from $14.7 million in Q4 2025.
Acrivon Therapeutics (ACRV) Research & Development (2022 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Research & Development for 5 consecutive years, with $15.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 1.61% year-over-year to $15.2 million; the TTM figure through Mar 2026 stood at $59.7 million (down 12.06% YoY), while the FY2025 annual figure was $60.0 million, down 6.25% from the prior year.
- Research & Development climbed to $15.2 million in Q1 2026 per ACRV's latest filing, from $14.7 million in the prior quarter.
- Across five years, Research & Development topped out at $18.9 million in Q3 2024 and bottomed at $9.8 million in Q1 2023.
- Historically, Research & Development has averaged $14.5 million across 5 years, with a median of $15.1 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development surged 83.73% — and 2025, when it slipped 27.65%.
- Acrivon Therapeutics' Research & Development stood at $18.4 million in 2022, then declined by 16.1% to $15.5 million in 2023, then grew by 20.36% to $18.6 million in 2024, then dropped by 20.85% to $14.7 million in 2025, then gained by 2.85% to $15.2 million in 2026.
- Business Quant data shows ACRV's Research & Development at $15.2 million in Q1 2026, $14.7 million in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 13.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.84 Mn |
| Mar 31, 2026 | 15.17 Mn |
| Dec 31, 2025 | 14.75 Mn |
| Sep 30, 2025 | 13.65 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 15.41 Mn |
| Dec 31, 2024 | 18.63 Mn |
| Sep 30, 2024 | 18.86 Mn |
| Jun 30, 2024 | 15.03 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | 15.48 Mn |
| Sep 30, 2023 | 10.27 Mn |
| Jun 30, 2023 | 10.52 Mn |
| Mar 31, 2023 | 9.76 Mn |
| Dec 31, 2022 | 18.45 Mn |